Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MASTERS-2 MultiStem Administration for Stroke Treatment and Enhanced Recovery
2019-001680-69Phase 3Active
- Sponsor
- Athersys, Inc.
- Start
- Sep 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing MultiStem with Placebo / standard care control (2 arms). Primary endpoint: mRS score. Started Sep 2020; status: active.
02
Drugs
invimestrocel
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2019-001680-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001680-69.